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ABSTRACT 
Monascuspurpureus is a non-pathogenic fungus that can produce statin called 
simvastatin, which can lower blood cholesterol level. The objectives of this research 
were to explore the potential of agricultural product on simvastatin and identify the 
optimal condition of simvastatin production in solid-state fermentation by 
Monascuspurpureus FTC 5356. The local agricultural products used were banana, 
guava, pumpkin, coconut meat, corn and papaya. Initially, the local agricultural 
products were ground and the initial moisture content of the agricultural products was 
fixed at 50% and pH 6. The mixtures were then incubated at 30°C for 11 days. Later, 
variety conditions of initial moisture content and nitrogen supplementation were 
introduced and examined on the simvastatin. Further experimental work was carried 
out using Central Composite Design (CCD) of Response Surface Methodology (RSM), 
with two factors of initial moisture content and nitrogen source. The results suggested 
that, among the agricultural products tested; only corn powder was able to produce 
simvastatin. The optimal condition for simvastatin production on corn was at 50% 
initial moisture content with supplementation of 0.2% nitrogen source.  
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1.0 INTRODUCTION 
Statins are a group of drugs that mainly used in lowering blood cholesterol. Statins are 
generally capable of bringing down the cholesterol level by from 20% to 60%. The 
discovery of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A),which acts as 
inhibitors was a step forward in the prevention of hypercholesterolemia and related 
diseases such as atherosclerosis, peripheral arterial disease, cerebro vascular disease, 
sepsis, ischemic disease and bone fracture (Khaled, 2007; Sultana et al., 2010). Recently, 
cardiovascular diseases are the major causes of death. Hence, there is a need for in 
developing processes for production of statins with approval by the Food and Drug 
Administration (FDA). 
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